Antiretrovirals

Zelalem Temesgen, Alan J. Wright

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Deaths related to the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome and the incidence of opportunistic infections have been drastically decreased in the industrialized world. These reductions are mainly due to recent advances in the management of HIV infection, including the availability of new therapies. Until November 1995, the antiretroviral drugs available and approved by the Food and Drug Administration for clinical use in the United States consisted of only four nucleoside analogue reverse transcriptase inhibitors: zidovudine, zalcitabine, didanosine, and stavudine. Since then, 2 new classes of agents and 10 new agents have been approved; thus, the number of available antiretroviral drugs has more than tripled. Additional drugs and newer classes of antiretrovirals are in various stages of development. Because of the availability of more drugs, the complexity of HIV treatment has increased. Selecting an appropriate antiretroviral therapeutic regimen involves addressing multiple interdependent issues, including patient adherence, pharmacokinetic properties of the drugs (including food effects and drug-drug interactions), drug resistance, and overlapping adverse effects.

Original languageEnglish (US)
Pages (from-to)1284-1301
Number of pages18
JournalMayo Clinic Proceedings
Volume74
Issue number12
StatePublished - 1999

Fingerprint

Pharmaceutical Preparations
HIV
Zalcitabine
Stavudine
Didanosine
Reverse Transcriptase Inhibitors
Zidovudine
Opportunistic Infections
Virus Diseases
United States Food and Drug Administration
Patient Compliance
Drug Interactions
Nucleosides
Drug Resistance
Acquired Immunodeficiency Syndrome
Pharmacokinetics
Food
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Temesgen, Z., & Wright, A. J. (1999). Antiretrovirals. Mayo Clinic Proceedings, 74(12), 1284-1301.

Antiretrovirals. / Temesgen, Zelalem; Wright, Alan J.

In: Mayo Clinic Proceedings, Vol. 74, No. 12, 1999, p. 1284-1301.

Research output: Contribution to journalArticle

Temesgen, Z & Wright, AJ 1999, 'Antiretrovirals', Mayo Clinic Proceedings, vol. 74, no. 12, pp. 1284-1301.
Temesgen Z, Wright AJ. Antiretrovirals. Mayo Clinic Proceedings. 1999;74(12):1284-1301.
Temesgen, Zelalem ; Wright, Alan J. / Antiretrovirals. In: Mayo Clinic Proceedings. 1999 ; Vol. 74, No. 12. pp. 1284-1301.
@article{a58c8ff21aaa4933acea0228783afa22,
title = "Antiretrovirals",
abstract = "Deaths related to the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome and the incidence of opportunistic infections have been drastically decreased in the industrialized world. These reductions are mainly due to recent advances in the management of HIV infection, including the availability of new therapies. Until November 1995, the antiretroviral drugs available and approved by the Food and Drug Administration for clinical use in the United States consisted of only four nucleoside analogue reverse transcriptase inhibitors: zidovudine, zalcitabine, didanosine, and stavudine. Since then, 2 new classes of agents and 10 new agents have been approved; thus, the number of available antiretroviral drugs has more than tripled. Additional drugs and newer classes of antiretrovirals are in various stages of development. Because of the availability of more drugs, the complexity of HIV treatment has increased. Selecting an appropriate antiretroviral therapeutic regimen involves addressing multiple interdependent issues, including patient adherence, pharmacokinetic properties of the drugs (including food effects and drug-drug interactions), drug resistance, and overlapping adverse effects.",
author = "Zelalem Temesgen and Wright, {Alan J.}",
year = "1999",
language = "English (US)",
volume = "74",
pages = "1284--1301",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Antiretrovirals

AU - Temesgen, Zelalem

AU - Wright, Alan J.

PY - 1999

Y1 - 1999

N2 - Deaths related to the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome and the incidence of opportunistic infections have been drastically decreased in the industrialized world. These reductions are mainly due to recent advances in the management of HIV infection, including the availability of new therapies. Until November 1995, the antiretroviral drugs available and approved by the Food and Drug Administration for clinical use in the United States consisted of only four nucleoside analogue reverse transcriptase inhibitors: zidovudine, zalcitabine, didanosine, and stavudine. Since then, 2 new classes of agents and 10 new agents have been approved; thus, the number of available antiretroviral drugs has more than tripled. Additional drugs and newer classes of antiretrovirals are in various stages of development. Because of the availability of more drugs, the complexity of HIV treatment has increased. Selecting an appropriate antiretroviral therapeutic regimen involves addressing multiple interdependent issues, including patient adherence, pharmacokinetic properties of the drugs (including food effects and drug-drug interactions), drug resistance, and overlapping adverse effects.

AB - Deaths related to the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome and the incidence of opportunistic infections have been drastically decreased in the industrialized world. These reductions are mainly due to recent advances in the management of HIV infection, including the availability of new therapies. Until November 1995, the antiretroviral drugs available and approved by the Food and Drug Administration for clinical use in the United States consisted of only four nucleoside analogue reverse transcriptase inhibitors: zidovudine, zalcitabine, didanosine, and stavudine. Since then, 2 new classes of agents and 10 new agents have been approved; thus, the number of available antiretroviral drugs has more than tripled. Additional drugs and newer classes of antiretrovirals are in various stages of development. Because of the availability of more drugs, the complexity of HIV treatment has increased. Selecting an appropriate antiretroviral therapeutic regimen involves addressing multiple interdependent issues, including patient adherence, pharmacokinetic properties of the drugs (including food effects and drug-drug interactions), drug resistance, and overlapping adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0032734960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032734960&partnerID=8YFLogxK

M3 - Article

C2 - 10593358

AN - SCOPUS:0032734960

VL - 74

SP - 1284

EP - 1301

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -